Product features

• Compact and convenient carbon dioxide monitor — simple and lightweight design, suitable for first-hand control, brings you unparalleled mobility and comfort, suitable for short-term EtCO2 monitoring for adults, children and infants
• It can be flexibly used in multiple medical care points, including pre hospital care, first-aid administration, operating room, intensive care unit and long-term acute disease care
• Help clinicians evaluate the effectiveness of CPR and provide guidance for ventilation treatment, so as to adjust according to each breath during treatment
• Durable, water-resistant design for reliable operation in challenging environments
• Easy maintenance – no routine calibration required

Masimo Rad-57 Features

• You can customize the default power on settings
• Provide more than 10 hours of continuous battery life
• Up to 72 hours of trend data storage
• FastSat can track the rapid changes of arterial O2 with unparalleled fidelity
• SmartTone buzzes synchronously with the pulse (even when the patient is moving)
• The three sensitivity options of APOD, “normal” and “”, can flexibly support various clinical applications
• Almost all false alarms can be ruled out without omitting real clinical events

• It is used for strict oxygen inhalation treatment and accurate pulse and blood oxygen monitoring to reduce the recurrence of hyperoxia and hypooxia, reduce the incidence of severe neonatal retinopathy (ROP), and also reduce the rate of false alarm
• It is used to monitor severe neonatal diseases such as left atrial hypoplasia
• It is used for cyanotic congenital heart disease patients and screening for congenital heart disease
• Used for nursing monitoring of patients with low perfusion during special period

Why neonatal screening is necessary
As we all know, the incidence of congenital heart disease is about 1%, of which 1/3 is severe congenital heart disease. Severe congenital heart disease includes two categories: one is critical congenital heart disease, which will die if not intervened in the neonatal period; The other is severe congenital heart disease, which will also die if not intervened within 1 year old.
The purpose of neonatal screening is to detect severe congenital heart disease at an early stage. Research in western countries shows that if screening is not carried out, the missed diagnosis rate of neonatal critical congenital heart disease before delivery can reach 30%. Delayed diagnosis led to a neonatal mortality rate of 38.8% and a mortality rate of 50.6% at 3 months, while timely diagnosis reduced the mortality rate to 20% at 3 months.
How to perform neonatal screening
The neonatal congenital heart screening should be completed within 24-48 hours after birth. If it is found that the blood oxygen is low and does not recover within 24 hours after birth (the blood oxygen saturation of normal newborns can reach 85~95% within 10 minutes after birth), the color Doppler echocardiography can be carried out at an early stage to find out whether there is a heart problem as soon as possible, which will help the clinical diagnosis.
Newborn congenital heart disease screening objects: newborns 24-48 hours after birth
Measurement position of neonatal congenital heart screening: right hand or any foot of the measuring object
Newborn congenital heart screening parameters: SpO2 (blood oxygen saturation), PI (blood perfusion index)
Newborn congenital heart screening steps:

1. Step 1: In front of the catheter (right hand)
   Place the sensor on the outer side of the right hand, under the fourth or fifth finger, wrap the detection part with tape, and ensure that the transmitter is aligned with the detector

2. Step 2: Record SpO2 and PI
3. Step 3: Behind the catheter (left or right foot)
   Place the sensor on the outer side of one foot, under the fourth and fifth toes, wrap the detection part with tape, and ensure that the transmitter and detector are aligned

4. Step 4: Record SpO2 and PI
5. Step 5: CCHD screening results

Pleth variability index (PVI) is a breakthrough measurement technology, which can help clinicians to evaluate the infusion status of patients noninvasive and continuously, effectively conduct fluid management, evaluate the perfusion status of patients to reflect the patient’s volume level, and monitor the trend and effect of liquid therapy. Under the condition of mechanical ventilation or intubation, the PVI value should be between 9 and 14, and under normal conditions, the PVI value should be between 14 and 25.
MAXIME CANNESSON, associate professor of anesthesiology in the Department of Anesthesiology and Perioperative Nursing at the University of California, Irvine, put forward: “It has been proved that PVI has a high accuracy in distinguishing between those who respond to infusion and those who do not, which is the only opportunity to improve the cardiac function and organ blood flow perfusion level by better managing the infusion volume of patients.”

• Infusion management is very important to improve the condition of patients
• The traditional methods to guide infusion management are usually unable to predict infusion reaction
• Newer methods can accurately predict responses, but are invasive or costly
• It has been proved that PVI can help clinicians predict the infusion reaction of patients receiving mechanical oxygen transfusion during surgery, intensive care and general anesthesia
• It has been proved that PVI can help clinicians improve infusion management and reduce lactic acid level compared with standard nursing care

Clinical advantages of PVI

As shown in the figure, PVI has a similar accuracy (0.94) of pulse pressure changes measured during invasive arterial intubation (0.93 area below the curve), which is higher than the heart index (0.56), central vein pressure (0.42) and pulmonary capillary wedge pressure (0.40).
It is confirmed that according to the definition that the cardiac output increases significantly after infusion management, PVI can help clinicians predict the infusion reaction of patients receiving mechanical oxygen infusion under general anesthesia.

• If PVI before capacity expansion> 14%, it can be predicted that the patient will have infusion reaction (81% sensitivity)
• If PVI before capacity expansion< 14%, it can be predicted that the patient will not have infusion reaction (100% specificity)

The higher the PVI value, the more likely the patient is to have infusion reaction. The PVI threshold is 14%. If it is greater than 14%, you can take more active steps to replenish albumin or colloidal solution; If the infusion rate is less than 14%, the infusion rate should be slowed down.

Clinical application of PVI

PVI can effectively assist doctors in fluid management, evaluate patients’ perfusion status to reflect patients’ capacity level, and monitor the trend and effect of fluid therapy through single site monitoring. It can be observed in cooperation with PI.
——Noninvasive monitoring tool for continuous evaluation of local tissue perfusion and systemic circulation perfusion.

• Evaluation of local tissue perfusion:
  PI will change when the local blood flow changes due to the contraction or expansion of skin vessels at the monitoring site. PI can confirm the analgesic effect of epidural anesthesia

• Evaluate systemic perfusion:
  Real time monitoring of physiological conditions is conducted by observing the trend change of PI. The significant decrease of patients’ peripheral circulation indicates clinically important physiological changes, including potential hypothermia, hypovolemia, shock and sepsis.
  For example: evaluation of circulatory function of severed fingers or limbs, limb vascular injury or infarction, vasculitis, vascular stenosis, edema, Raynaud’s disease, regional block, etc

• The greater the PI value, the better the perfusion condition
• PI Normal> 1.0%； Masimo SET can measure 0.02%~20%

PVI measurement technology platform — pulse carbon oxygen blood oxygen detector

Masimo rainbow SET technology is a globally recognized “gold standard” technology for pulse blood oxygen. It has high sensitivity and specificity for antibody movement, anti hypothermia and low perfusion. In addition to providing Masimo SET Plus Oximeter for measurement under the condition of body movement and low blood perfusion, it is also a non-invasive monitoring platform, which can be used to evaluate a variety of blood components and physiological parameters. Previously, invasive or complex processes were required for evaluation.
Masimo SET technology (basic three parameters)

• SpO2
• PR
• PI (blood flow perfusion index)

Rainbow SET technology (Rainbow parameter)

• SpOC
• SpMet
• PVI
• SpHb (non-invasive total hemoglobin)
• SpCO

With the upgradable rainbow SET platform, you can now choose the appropriate rainbow measurement parameters without worrying about the investment in patients.

• More than 100 independent and objective studies have confirmed that the pulse oximeter using Masimo SET technology can provide accurate and reliable readings under the conditions of exercise and low blood perfusion
• The accuracy of Masimo SET pulse oximeter has been proved by facts. It can reduce 95% of false alarms without omitting real clinical events
• The simple and easy-to-use interface is convenient for quick setting and alarm management with touch programming
• Large LED color display is convenient for reading data from a long distance
• The compact and lightweight design is ideal for acute care and other care environments, including long-term care institutions, home care and sleep laboratories

Product Functions

• Sleep mode is easy to configure the system for clinical research
• Second average sleep mode
• Home mode allows safe, accurate monitoring and trending at home
• RadNet ? And RadLink ? Multi patient remote monitoring interface function
• Perfusion index (PI) indicates the arterial pulse signal strength, which can be used as a diagnostic tool in low permeability 1
• Low signal IQ ? (SIQ) indicators highlight the conditions of low signal quality
• FastSat Tracking rapid changes with high fidelity and other arterial oxygen pulse oximeters
• APOD (Adaptive detector detection) provides three sensitivity modes for Masimo’s probe detection – APOD, normal and sensitivity
• Adjustable average interval time is 2 to 16 seconds
• Nurse call interface
• Battery life at 7 hours of internal full charge
• 72 hour trend memory
• Can be configured horizontally and vertically
• Compatible with Philips Vuelink device interface module

• Through clinical verification, it can provide accurate pulse blood oxygen measurement in the process of body movement and low blood flow perfusion
• Lightweight and convenient handheld device with long battery life
• Support quick measurement at startup
• The indicator bar can identify the signal and indicate the signal quality when the patient has body movement and low signal to noise ratio
• The blood perfusion index (PI) indicates the strength of the arterial pulse signal and can assist in the selection of the detection site
• Multiple sensor options for various clinical applications
• The battery indicator provides visual power notification

Masimo Radical-7 Application

• Operating room: assess anemia status and conduct blood transfusion management
• ICU: assess anemia status, confirm hemoglobin changes, and timely detect bleeding
• Emergency room: assess the anemia status and determine the treatment plan needed
• Neonatology: neonatal congenital screening

Masimo new generation brain function monitoring system approved by FDA

Masimo is a global leader in non-invasive monitoring technology, trying to improve patient conditions at a lower cost. Joe Kiani, founder and CEO of Masimo, said that he expected the new generation SedLine to play an important role as another Masimo product, the SET blood oxygen detector.

SedLine equipment has been listed in the United States for more than 10 years, and was acquired by Masimo in 2010. Masimo first worked with Massachusetts General Hospital (MGH) to develop multiple brain wave analysis. In 2016, it reached technical cooperation with Philips, combining with Philips IntelliVue display, to highlight the brain response of patients after anesthesia.